Access Pharmaceuticals Featured on Onclive.Com
ACCESS PHARMACEUTICALS, INC., a developer of new products for oncology supportive care, announced that its novel product for oral mucositis, MuGard®, has been featured in an article on OncLive.com titled, “Study Finds Mouth Rinse Alleviates Oral Mucositis Symptoms in Head and Neck Cancers.” Dr. Steve Sonis, a leading expert in oral mucositis, provides insight on the growing demand seen in the oncology community for evidence-based strategies for the debilitating anticancer regimen side effect.Access Pharmaceuticals Receives 510(K) FDA Marketing Clearance for Proctigard
ACCESS PHARMACEUTICALS, INC., a developer of new products for oncology supportive care, announced today that it has received 510(K) marketing clearance from the U.S. Food and Drug Administration (FDA) for ProctiGard™, its novel treatment for symptomatic management of rectal mucositis. The Company indicated its development of ProctiGard™ is a direct response to dialogue with the oncology community that is looking for better, more treatment options for rectal mucositis and radiation proctitis, a debilitating oncology side effect. Access believes that ProctiGard is a first-in-class treatment option that addresses a significant unmet medical need. Access currently holds global commercialization rights for ProctiGard.